Supernus Pharma (SUPN) Reports Q4 EPS of $0.04

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Supernus Pharma (SUPN) Reports Q4 EPS of $0.04

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results

April 13, 2022 4:11 PM EDT

Annual Report on Form 10-K filed on April 13, 2022Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022

ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today filed its Annual Report on Form 10-K and reported final audited financial results for the fourth quarter and full year ended December 31, 2021.

On February 28, 2022, the Company announced preliminary unaudited results... More